Top Markets
#1 Brevis Brevis +35.04%
#2 Keep Network Keep Network +28.96%
#3 Talus Network Talus Network +28.51%
#4 Tung Tung Tung Sahur Tung Tung Tung Sahur +26.94%
#5 MemeCore MemeCore +25.40%
#6 Infinity Ground Infinity Ground +21.91%
#7 Synapse Synapse +21.54%
#8 Cortex Cortex +20.78%
#9 Starpower Starpower +20.19%
#10 Allora Allora +18.82%
Coin of the day
Brevis Brevis
Settings
Language
ENGLISH
Currency
USD
Theme
IntegraGen SA IntegraGen SA

IntegraGen SA

ALINT
Rank in Stocks #19673
IntegraGen SA provides human genome analysis services for academic researcher... IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
Share Price
$0.20342561
Market Cap
$1.34M
Change (1 day)
-1.44%
Change (1 year)
-65.74%
Country
FR
Trade IntegraGen SA (ALINT)

Category

Healthcare
P/S ratio for IntegraGen SA (ALINT)
P/S ratio as of July 2026 TTM: 0.23
According to IntegraGen SA latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.23. At the end of 2023 the company had a P/S ratio of 0.47.
P/S ratio history for IntegraGen SA from 2008 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.23 -48.57%
2024 0.44 -7.21%
2023 0.47 -22.57%
2022 0.61 -5.95%
2021 0.65 -57.32%
2020 1.52 91.72%
2019 0.79 -23.34%
2018 1.03 -58.87%
2017 2.51 -7.49%
2016 2.71 -30.91%
2015 3.93 -9.01%
2014 4.32 23.38%
2013 3.50 -42.44%
2012 6.08 -6.36%
2011 6.49 -5.08%
2010 6.84 -28.72%
2009 9.59 -19.67%
2008 11.94 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
4.26 1,784.05%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.29 4,445.91%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
4.31 1,802.61%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.44 2,747.06%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
16.96 7,394.12%
NL